Population pharmacokinetics of cisapride in neonates
We conducted a population pharmacokinetic analysis of cisapride in neonates to study whether metabolic immaturity in this population may lead to increased concentrations. Cisapride was administered orally in 91 neonates at the dose of 0.2 mg/kg four times a day. Plasma concentrations were measured u...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 2002-11, Vol.58 (8), p.507-513 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 513 |
|---|---|
| container_issue | 8 |
| container_start_page | 507 |
| container_title | European journal of clinical pharmacology |
| container_volume | 58 |
| creator | ODOUL, F LE GUELLEC, C HENROT, A SALIBA, E LEVRON, J. C SAUX, M. C PAINTAUD, G AUTRET-LECA, E |
| description | We conducted a population pharmacokinetic analysis of cisapride in neonates to study whether metabolic immaturity in this population may lead to increased concentrations.
Cisapride was administered orally in 91 neonates at the dose of 0.2 mg/kg four times a day. Plasma concentrations were measured using a validated HPLC method. A one-compartment model with first-order absorption was fitted to the data using NONMEM software.
One to seven plasma samples were obtained from neonates aged 7-123 days. Cisapride concentrations ranged from 5.5 ng/mL to 172 ng/mL and were not higher than those reported in adults. The absorption constant rate was fixed to 2.5 h-1. Clearance (CL/F) and volume of distribution (V/F) both significantly correlated to weight (WT), but addition of this covariate in V/F did not improve the objective function after it was added in the CL/F covariate model. Prematurity, postnatal age, or coadministered drugs did not affect cisapride clearance. Final population pharmacokinetic parameters (interindividual variability) were: V/F=17,200 mL (90.4%) and CL/F=3.91 x WT(3/4) mL/h (36.3%).
Our finding that cisapride clearance is primarily influenced by weight is in agreement with current recommendations of weight-adjusted doses. This study indicates that no clinically relevant maturational changes in cisapride clearance have to be considered during the first quadrimester of life. |
| doi_str_mv | 10.1007/s00228-002-0504-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_214480685</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>819128571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-bb4d210f8509ec539feb01c43b390f2f85ee3f3f4b89c74e2d1f372903cba43f3</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhoMotlZ_gBdZBI_RmWS2u3uU4hcU9KDnkM0muLXdrMnuwf56U1roZQYmz0xeHsauEe4RoHiIAEKUPFUOORDfnrApkhQcgfCUTQEk8nlVwIRdxLgCwLwCec4mKChHEsWU0Yfvx7UeWt9l_bcOG238T9vZoTUx8y4zbdR9aBubtV3WWd_pwcZLdub0OtqrQ5-xr-enz8UrX76_vC0el9zInAZe19QIBFfmUFmTy8rZGtCQrGUFTqS5tdJJR3VZmYKsaNDJQqSIptaUXmbsdn-3D_53tHFQKz-GLn2pBBKVMC_zBOEeMsHHGKxTKe9Ghz-FoHaa1F6TSlXtNKlt2rk5HB7rjW2OGwcvCbg7ADoavXZBd8nEkaNdThTyH1VJb14</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214480685</pqid></control><display><type>article</type><title>Population pharmacokinetics of cisapride in neonates</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>ODOUL, F ; LE GUELLEC, C ; HENROT, A ; SALIBA, E ; LEVRON, J. C ; SAUX, M. C ; PAINTAUD, G ; AUTRET-LECA, E</creator><creatorcontrib>ODOUL, F ; LE GUELLEC, C ; HENROT, A ; SALIBA, E ; LEVRON, J. C ; SAUX, M. C ; PAINTAUD, G ; AUTRET-LECA, E</creatorcontrib><description>We conducted a population pharmacokinetic analysis of cisapride in neonates to study whether metabolic immaturity in this population may lead to increased concentrations.
Cisapride was administered orally in 91 neonates at the dose of 0.2 mg/kg four times a day. Plasma concentrations were measured using a validated HPLC method. A one-compartment model with first-order absorption was fitted to the data using NONMEM software.
One to seven plasma samples were obtained from neonates aged 7-123 days. Cisapride concentrations ranged from 5.5 ng/mL to 172 ng/mL and were not higher than those reported in adults. The absorption constant rate was fixed to 2.5 h-1. Clearance (CL/F) and volume of distribution (V/F) both significantly correlated to weight (WT), but addition of this covariate in V/F did not improve the objective function after it was added in the CL/F covariate model. Prematurity, postnatal age, or coadministered drugs did not affect cisapride clearance. Final population pharmacokinetic parameters (interindividual variability) were: V/F=17,200 mL (90.4%) and CL/F=3.91 x WT(3/4) mL/h (36.3%).
Our finding that cisapride clearance is primarily influenced by weight is in agreement with current recommendations of weight-adjusted doses. This study indicates that no clinically relevant maturational changes in cisapride clearance have to be considered during the first quadrimester of life.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-002-0504-z</identifier><identifier>PMID: 12451427</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Biological and medical sciences ; Cisapride - administration & dosage ; Cisapride - adverse effects ; Cisapride - blood ; Digestive system ; Female ; Humans ; Infant, Newborn - metabolism ; Male ; Medical sciences ; Metabolic Clearance Rate ; Models, Biological ; Pharmacology. Drug treatments ; Prospective Studies</subject><ispartof>European journal of clinical pharmacology, 2002-11, Vol.58 (8), p.507-513</ispartof><rights>2003 INIST-CNRS</rights><rights>Springer-Verlag 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-bb4d210f8509ec539feb01c43b390f2f85ee3f3f4b89c74e2d1f372903cba43f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14372912$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12451427$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ODOUL, F</creatorcontrib><creatorcontrib>LE GUELLEC, C</creatorcontrib><creatorcontrib>HENROT, A</creatorcontrib><creatorcontrib>SALIBA, E</creatorcontrib><creatorcontrib>LEVRON, J. C</creatorcontrib><creatorcontrib>SAUX, M. C</creatorcontrib><creatorcontrib>PAINTAUD, G</creatorcontrib><creatorcontrib>AUTRET-LECA, E</creatorcontrib><title>Population pharmacokinetics of cisapride in neonates</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>We conducted a population pharmacokinetic analysis of cisapride in neonates to study whether metabolic immaturity in this population may lead to increased concentrations.
Cisapride was administered orally in 91 neonates at the dose of 0.2 mg/kg four times a day. Plasma concentrations were measured using a validated HPLC method. A one-compartment model with first-order absorption was fitted to the data using NONMEM software.
One to seven plasma samples were obtained from neonates aged 7-123 days. Cisapride concentrations ranged from 5.5 ng/mL to 172 ng/mL and were not higher than those reported in adults. The absorption constant rate was fixed to 2.5 h-1. Clearance (CL/F) and volume of distribution (V/F) both significantly correlated to weight (WT), but addition of this covariate in V/F did not improve the objective function after it was added in the CL/F covariate model. Prematurity, postnatal age, or coadministered drugs did not affect cisapride clearance. Final population pharmacokinetic parameters (interindividual variability) were: V/F=17,200 mL (90.4%) and CL/F=3.91 x WT(3/4) mL/h (36.3%).
Our finding that cisapride clearance is primarily influenced by weight is in agreement with current recommendations of weight-adjusted doses. This study indicates that no clinically relevant maturational changes in cisapride clearance have to be considered during the first quadrimester of life.</description><subject>Biological and medical sciences</subject><subject>Cisapride - administration & dosage</subject><subject>Cisapride - adverse effects</subject><subject>Cisapride - blood</subject><subject>Digestive system</subject><subject>Female</subject><subject>Humans</subject><subject>Infant, Newborn - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic Clearance Rate</subject><subject>Models, Biological</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpFkE1LAzEQhoMotlZ_gBdZBI_RmWS2u3uU4hcU9KDnkM0muLXdrMnuwf56U1roZQYmz0xeHsauEe4RoHiIAEKUPFUOORDfnrApkhQcgfCUTQEk8nlVwIRdxLgCwLwCec4mKChHEsWU0Yfvx7UeWt9l_bcOG238T9vZoTUx8y4zbdR9aBubtV3WWd_pwcZLdub0OtqrQ5-xr-enz8UrX76_vC0el9zInAZe19QIBFfmUFmTy8rZGtCQrGUFTqS5tdJJR3VZmYKsaNDJQqSIptaUXmbsdn-3D_53tHFQKz-GLn2pBBKVMC_zBOEeMsHHGKxTKe9Ghz-FoHaa1F6TSlXtNKlt2rk5HB7rjW2OGwcvCbg7ADoavXZBd8nEkaNdThTyH1VJb14</recordid><startdate>20021101</startdate><enddate>20021101</enddate><creator>ODOUL, F</creator><creator>LE GUELLEC, C</creator><creator>HENROT, A</creator><creator>SALIBA, E</creator><creator>LEVRON, J. C</creator><creator>SAUX, M. C</creator><creator>PAINTAUD, G</creator><creator>AUTRET-LECA, E</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20021101</creationdate><title>Population pharmacokinetics of cisapride in neonates</title><author>ODOUL, F ; LE GUELLEC, C ; HENROT, A ; SALIBA, E ; LEVRON, J. C ; SAUX, M. C ; PAINTAUD, G ; AUTRET-LECA, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-bb4d210f8509ec539feb01c43b390f2f85ee3f3f4b89c74e2d1f372903cba43f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Cisapride - administration & dosage</topic><topic>Cisapride - adverse effects</topic><topic>Cisapride - blood</topic><topic>Digestive system</topic><topic>Female</topic><topic>Humans</topic><topic>Infant, Newborn - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic Clearance Rate</topic><topic>Models, Biological</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ODOUL, F</creatorcontrib><creatorcontrib>LE GUELLEC, C</creatorcontrib><creatorcontrib>HENROT, A</creatorcontrib><creatorcontrib>SALIBA, E</creatorcontrib><creatorcontrib>LEVRON, J. C</creatorcontrib><creatorcontrib>SAUX, M. C</creatorcontrib><creatorcontrib>PAINTAUD, G</creatorcontrib><creatorcontrib>AUTRET-LECA, E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ODOUL, F</au><au>LE GUELLEC, C</au><au>HENROT, A</au><au>SALIBA, E</au><au>LEVRON, J. C</au><au>SAUX, M. C</au><au>PAINTAUD, G</au><au>AUTRET-LECA, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Population pharmacokinetics of cisapride in neonates</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>2002-11-01</date><risdate>2002</risdate><volume>58</volume><issue>8</issue><spage>507</spage><epage>513</epage><pages>507-513</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>We conducted a population pharmacokinetic analysis of cisapride in neonates to study whether metabolic immaturity in this population may lead to increased concentrations.
Cisapride was administered orally in 91 neonates at the dose of 0.2 mg/kg four times a day. Plasma concentrations were measured using a validated HPLC method. A one-compartment model with first-order absorption was fitted to the data using NONMEM software.
One to seven plasma samples were obtained from neonates aged 7-123 days. Cisapride concentrations ranged from 5.5 ng/mL to 172 ng/mL and were not higher than those reported in adults. The absorption constant rate was fixed to 2.5 h-1. Clearance (CL/F) and volume of distribution (V/F) both significantly correlated to weight (WT), but addition of this covariate in V/F did not improve the objective function after it was added in the CL/F covariate model. Prematurity, postnatal age, or coadministered drugs did not affect cisapride clearance. Final population pharmacokinetic parameters (interindividual variability) were: V/F=17,200 mL (90.4%) and CL/F=3.91 x WT(3/4) mL/h (36.3%).
Our finding that cisapride clearance is primarily influenced by weight is in agreement with current recommendations of weight-adjusted doses. This study indicates that no clinically relevant maturational changes in cisapride clearance have to be considered during the first quadrimester of life.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>12451427</pmid><doi>10.1007/s00228-002-0504-z</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 2002-11, Vol.58 (8), p.507-513 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_journals_214480685 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Biological and medical sciences Cisapride - administration & dosage Cisapride - adverse effects Cisapride - blood Digestive system Female Humans Infant, Newborn - metabolism Male Medical sciences Metabolic Clearance Rate Models, Biological Pharmacology. Drug treatments Prospective Studies |
| title | Population pharmacokinetics of cisapride in neonates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T19%3A23%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Population%20pharmacokinetics%20of%20cisapride%20in%20neonates&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=ODOUL,%20F&rft.date=2002-11-01&rft.volume=58&rft.issue=8&rft.spage=507&rft.epage=513&rft.pages=507-513&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-002-0504-z&rft_dat=%3Cproquest_cross%3E819128571%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214480685&rft_id=info:pmid/12451427&rfr_iscdi=true |